Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12.

Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.